T8712

1-Palmitoyl-sn-glycero-3-phosphocholine (16:0 Lyso PC) is a pro-inflammatory lysophosphatidylcholine that can be used in atherosclerosis research.

Compound 8a (PDE10A-IN-3) serves as an inhibitor of phosphodiesterase 10A (PDE10A) and is utilized in schizophrenia research [1].

PDE1-IN-6 (compound 6c) functions as a highly selective PDE1 inhibitor, exhibiting an IC 50 value of 7.5 nM. It notably inhibits proliferation and induces apoptosis in acute myelogenous leukemia cells [1].

PDE1-IN-7 (Compound 13h), with an IC50 value of 10 nM, selectively inhibits bPDE1. This compound demonstrates significant anti-fibrotic effects in a BDL-induced liver fibrosis rat model and is useful for research purposes in studying liver fibrosis [1].

PDK4-IN-2 (compound 8), a pyruvate dehydrogenase kinase 4 (PDK4) inhibitor, exhibits an inhibition concentration (IC 50) of 46 µM. By regulating bioenergetics and activating the tricarboxylic acid cycle [1], it enhances the ejection fraction in failing hearts.

PDM-042 is a potent and selective orally active phosphodiesterase 10A (PDE10A) inhibitor, demonstrating strong inhibitory activities for human and rat PDE10A with IC50 values below 1 nM and over 1000-fold selectivity against other phosphodiesterases. PDM-042 can be used for schizophrenia research [1].